Felix Frueh says that patients are not the barrier to wide use of genetic tests. In a discussion of personalized medicine at CONVERGE, he said that he has absolute confidence in the willingness of patients to participate.
He described a Medco program that connected doctors and patients with genetic tests. Doctors and patients were both contacted in real time when a patient filled a prescription for a drug for which there was a test to guide therapy.
With the Rise of AI, What IP Disputes in Healthcare Are Likely to Emerge?
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
He described two separate reactions to the program. To find out which group had an 85 percent acceptance rate of the test, watch the video.
Frueh is the entrepreneur-in-residence at Third Rock Ventures. He provides strategic input on new and existing portfolio companies with a particular focus on personalized medicine.
Prior to joining Third Rock Ventures, Frueh was president of the Medco Research Institute and led outcomes-oriented research initiatives and collaborations. He also formed Medco’s personalized medicine research and development organization.
You can watch the entire video here.
